678 related articles for article (PubMed ID: 30026335)
1. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial.
Mathieu C; Dandona P; Gillard P; Senior P; Hasslacher C; Araki E; Lind M; Bain SC; Jabbour S; Arya N; Hansen L; Thorén F; Langkilde AM;
Diabetes Care; 2018 Sep; 41(9):1938-1946. PubMed ID: 30026335
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
Dandona P; Mathieu C; Phillip M; Hansen L; Griffen SC; Tschöpe D; Thorén F; Xu J; Langkilde AM;
Lancet Diabetes Endocrinol; 2017 Nov; 5(11):864-876. PubMed ID: 28919061
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study.
Dandona P; Mathieu C; Phillip M; Hansen L; Tschöpe D; Thorén F; Xu J; Langkilde AM;
Diabetes Care; 2018 Dec; 41(12):2552-2559. PubMed ID: 30352894
[TBL] [Abstract][Full Text] [Related]
4. Glucose Variables in Type 1 Diabetes Studies With Dapagliflozin: Pooled Analysis of Continuous Glucose Monitoring Data From DEPICT-1 and -2.
Mathieu C; Dandona P; Phillip M; Oron T; Lind M; Hansen L; Thorén F; Xu J; Langkilde AM;
Diabetes Care; 2019 Jun; 42(6):1081-1087. PubMed ID: 30967434
[TBL] [Abstract][Full Text] [Related]
5. Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials.
Groop PH; Dandona P; Phillip M; Gillard P; Edelman S; Jendle J; Xu J; Scheerer MF; Thoren F; Iqbal N; Repetto E; Mathieu C
Lancet Diabetes Endocrinol; 2020 Oct; 8(10):845-854. PubMed ID: 32946821
[TBL] [Abstract][Full Text] [Related]
6. Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: A randomized controlled trial.
Yang W; Ma J; Li Y; Li Y; Zhou Z; Kim JH; Zhao J; Ptaszynska A
J Diabetes; 2018 Jul; 10(7):589-599. PubMed ID: 29215189
[TBL] [Abstract][Full Text] [Related]
7. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
Henry RR; Rosenstock J; Edelman S; Mudaliar S; Chalamandaris AG; Kasichayanula S; Bogle A; Iqbal N; List J; Griffen SC
Diabetes Care; 2015 Mar; 38(3):412-9. PubMed ID: 25271207
[TBL] [Abstract][Full Text] [Related]
8. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
Wilding JP; Woo V; Rohwedder K; Sugg J; Parikh S;
Diabetes Obes Metab; 2014 Feb; 16(2):124-36. PubMed ID: 23911013
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period.
Araki E; Onishi Y; Asano M; Kim H; Ekholm E; Johnsson E; Yajima T
J Diabetes Investig; 2016 Jul; 7(4):555-64. PubMed ID: 27181422
[TBL] [Abstract][Full Text] [Related]
10. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.
Ji L; Ma J; Li H; Mansfield TA; T'joen CL; Iqbal N; Ptaszynska A; List JF
Clin Ther; 2014 Jan; 36(1):84-100.e9. PubMed ID: 24378206
[TBL] [Abstract][Full Text] [Related]
11. [Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin].
Wilding JP; Woo V; Soler NG; Pahor A; Sugg J; Rohwedder K; Parikh S;
Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S27-38. PubMed ID: 23529568
[TBL] [Abstract][Full Text] [Related]
12. Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial.
Henry RR; Strange P; Zhou R; Pettus J; Shi L; Zhuplatov SB; Mansfield T; Klein D; Katz A
Diabetes Technol Ther; 2018 Nov; 20(11):715-724. PubMed ID: 30222367
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.
Wilding JP; Woo V; Soler NG; Pahor A; Sugg J; Rohwedder K; Parikh S;
Ann Intern Med; 2012 Mar; 156(6):405-15. PubMed ID: 22431673
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial.
Mathieu C; Rudofsky G; Phillip M; Araki E; Lind M; Arya N; Thorén F; Scheerer MF; Iqbal N; Dandona P
Diabetes Obes Metab; 2020 Sep; 22(9):1516-1526. PubMed ID: 32311204
[TBL] [Abstract][Full Text] [Related]
15. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.
Weber MA; Mansfield TA; Cain VA; Iqbal N; Parikh S; Ptaszynska A
Lancet Diabetes Endocrinol; 2016 Mar; 4(3):211-220. PubMed ID: 26620248
[TBL] [Abstract][Full Text] [Related]
16. Long-term (52-week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the DEPICT-2 study.
Araki E; Mathieu C; Shiraiwa T; Maeda H; Ikeda H; Thoren F; Arya N; Asano M; Iqbal N
Diabetes Obes Metab; 2021 Jul; 23(7):1496-1504. PubMed ID: 33620762
[TBL] [Abstract][Full Text] [Related]
17. Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials.
Boeder S; Edelman SV
Diabetes Obes Metab; 2019 Apr; 21 Suppl 2(Suppl 2):62-77. PubMed ID: 31081593
[TBL] [Abstract][Full Text] [Related]
18. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.
Matthaei S; Bowering K; Rohwedder K; Grohl A; Parikh S;
Diabetes Care; 2015 Mar; 38(3):365-72. PubMed ID: 25592197
[TBL] [Abstract][Full Text] [Related]
19. Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes.
Matthaei S; Catrinoiu D; Celiński A; Ekholm E; Cook W; Hirshberg B; Chen H; Iqbal N; Hansen L
Diabetes Care; 2015 Nov; 38(11):2018-24. PubMed ID: 26324329
[TBL] [Abstract][Full Text] [Related]
20. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N
Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]